Wednesday, November 11, 2026
Via News Knowledge File

Elf Labs

organization80% conf.·synced Aug 13, 2026

IP-focused entertainment company controlling 500+ trademarks/copyrights for characters including Cinderella, Snow White, Rapunzel, Sleeping Beauty, and Peter Pan; over $15M in royalties

31
sourced metrics
0
relationships
18
stated objectives
0
Via News reports

Every fact below is drawn from Via News's knowledge graph and linked to the source document it came from. Nothing here is unsourced. How we source →

Key metrics · each point sourced

Country Licensing
30count
Trademarks Copyrights Owned
500assets
Countries Licensed
30count
⚠ sources conflictsource
Country Count
30countries
⚠ sources conflictsource
Country Expansion
30count
Country Presence
30countries
Distribution Countries
30countries
Geographic Reach
30countries
Intellectual Property
500trademarks_and_copyrights
Intellectual Property Count
500trademarks_copyrights
⚠ sources conflictsource
International Markets
30countries
Ip Assets
500trademarks_and_copyrights
Licensing Countries
30countries
⚠ sources conflictsource
Licensing Markets
30countries
Market Cap
1600USD
⚠ sources conflictsource
Market Expansion
30countries
Market Presence
30countries
Product Count
100product_lines

Stated objectives

Expand investor base through Regulation A+ offering at $0.85/share with $1,000 minimum investment to diversify portfolios into early-stage AI innovation

source
target: 0.85 per share stated

Scale AI marketing platform to help transform data chaos into actionable insights and create high-performing content with measurable ROI

source
stated

Generate measurable ROI for clients through AI-driven content creation and data analytics

source
stated

Provide investors exposure to rapidly growing AI and tech sector at ground-floor stage

source
target: 0.85 per share minimum investment of 1000 USD stated

Elf Labs scaling distribution through patented production systems, global licensing, and streaming and mobile initiatives toward public market listing

source
target: Nasdaq listing under ticker ELFS stated

Scaling distribution through patented production systems, global licensing, and streaming and mobile initiatives

source
stated

Scale distribution through patented production systems, global licensing, and streaming and mobile initiatives toward public market listing on Nasdaq

source
stated

Scaling distribution through patented production systems, global licensing, and streaming and mobile initiatives

source
stated

Scale distribution through patented production systems, global licensing, streaming and mobile initiatives toward public market transition

source
stated

Scale distribution through patented production systems, global licensing, streaming and mobile initiatives toward public market debut

source
stated
This Knowledge File is assembled from Via News's source-traceable knowledge graph. Metrics, objectives and relationships are extracted from primary and credible secondary documents and refreshed on a schedule. Read our methodology →
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Biotech Catalyst Wave: Late-2026 Clinical Readouts, PDUFA Dates and Capital Restructuring
A dense cluster of Q4 2026 to Q1 2027 clinical and regulatory catalysts spans hepatitis delta (Vir's ECLIPSE/SOLSTICE), hypertension and sleep apnea (Mineralys' lorundrostat, PDUFA 2026-12-22), severe hypertriglyceridemia (plozasiran), oncology (ivonescimab BLA, PDUFA 2026-11-14) and gene therapy (Krystal). Positive data flow from AASLD and AHA presentations is offset by cost-cutting guidance, milestones slipping into 2027, and a delisting process that signals capital-market stress for some issuers. Near-term value hinges on binary FDA decisions and Phase 3 topline readouts in Q1 2027.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,995
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,995 facts checked against source5,564 source documents archived
Query this data → isubstrate.com